Novavax vaccine gets first emergency use approval in Indonesia: Statement
Nov 02, 2021, at 05:45 am
Jakarta/UNI/Sputnik: US drug maker Novavax said on Monday that the Covid-19 vaccine it jointly developed with the Serum Institute of India has received the first authorization for emergency use in Indonesia.
SII to start production of Russia's Sputnik V vaccine from September
Jul 13, 2021, at 08:38 pm
Pune/IBNS: World's largest vaccine manufacturer, Serum Institute of India (SII), is all set to start the production of Russia's Sputnik V vaccine in India from September, said the CEO of Russian Direct Investment Fund (RDIF), Kirill Dmitriev.
Jun 26, 2021, at 06:18 am
Pune/IBNS: The Serum institute of India, which started manufacturing the first batch of Novavax's Covid-19 vaccine in India under the name Covavax, said "a new milestone has been reached".
Govt's expert panel clears Oxford COVID-19 vaccine for India
Jan 02, 2021, at 03:56 am
New Delhi/IBNS: A government-appointed panel of experts on Friday cleared the Oxford COVID-19 vaccine manufactured by the Serum Institute of India, which will be sent for approval to the regulator Drugs Controller General of India (DCGI).
Govt's expert panel to meet over Covid-19 vaccine approval today
Jan 01, 2021, at 04:30 pm
New Delhi/IBNS: An expert panel, appointed by the central government, will on Friday meet over the approval for an emergency use of three Covid-19 vaccines, including an indigenous one.
Serum Institute gets DCGI nod to resume Covid-19 vaccine
Sep 16, 2020, at 04:25 pm
New Delhi/IBNS: The Serum Institute of India (SII) has got the nod of the Drug Controller General of India (DCGI) to resume the phase two and three trials for Covid-19 vaccine, media reports said.
After Oxford Covid-19 Vaccine trial pause, DCGI sends show-cause notice to Serum Institute
Sep 10, 2020, at 04:23 am
New Delhi/IBNS: After pharmaceutical giant AstraZeneca halted the Phase 3 study testing of the Oxford Vaccine against Covid-19, the Drugs Controller General of India (DCGI) on Wednesday issued a show-cause notice to Serum Institute of India (SII) for not informing the central drug regulator about the pause of trials in other countries.